Oxaliplatin (Standard)

• UNSPSC Description:

  Oxaliplatin (Standard) is the analytical standard of Oxaliplatin. This product is intended for research and analytical applications. Oxaliplatin is a DNA synthesis inhibitor. Oxaliplatin causes DNA crosslinking damage, prevents DNA replication and transcription and induces apoptosis. Oxaliplatin can be used for cancer research[1][2][3].

• Target Antigen:

  Apoptosis; DNA/RNA Synthesis

• Type:

  Reference Standards

• Related Pathways:

  Apoptosis;Cell Cycle/DNA Damage

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/oxaliplatin-standard.html

• Smiles:

  O=C(O1)C(O[Pt]21[NH2][C@@H]3CCCC[C@H]3[NH2]2)=O

• Molecular Weight:

  397.29

• References & Citations:

  [1]Raymond E, et al. Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol. 1998 Oct;9(10):1053-71.|[2]Mohammed MQ, et al. Oxaliplatin is active in vitro against human melanoma cell lines: comparison with NSC 119875 and NSC 241240. Anticancer Drugs. 2000 Nov;11(10):859-63.|[3]Pendyala L, et al. In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin. Cancer Res. 1993 Dec 15;53(24):5970-6.|[4]Wang Z, et al. Oxaliplatin induces apoptosis in hepatocellular carcinoma cells and inhibits tumor growth. Expert Opin Investig Drugs. 2009 Nov;18(11):1595-604|[5]Mathé G, et al. Oxalato-platinum or 1-OHP, a third-generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cis-platinum. Biomed Pharmacother. 1989;43(4):237-50.|[6]Schellingerhout D, et al. Impairment of retrograde neuronal transport in oxaliplatin-induced neuropathy demonstrated by molecular imaging. PLoS One. 2012;7(9):e45776. doi: 10.1371/journal.pone.0045776. Epub 2012 Sep 20.|[7]Park GY, et al. Phenanthriplatin, a monofunctional DNA-binding platinum anticancer drug candidate with unusual potency and cellular activity profile. Proc Natl Acad Sci U S A. 2012 Jul 24;109(30):11987-92.|[8]Yi Yao, et al. Comparative proteomic analysis of colon cancer cells in response to oxaliplatin treatment. Biochim Biophys Acta. 2009 Oct;1794(10):1433-40.|[9]Garrett MJ, et, al. Capecitabine, Oxaliplatin, and Bevacizumab (BCapOx) Regimen for Metastatic Colorectal Cancer. Hosp Pharm. 2017 May;52(5):341-347.

• Shipping Conditions:

  Room temperature

• CAS Number:

  61825-94-3